Chile deal opens up South America for Sense Biodetection

Molecular diagnostics innovator Sense Biodetection, which has Cambridge operations, has entered into a strategic agreement with Biotecom for the non-exclusive distribution in Chile of Sense’s Veros instrument-free, point-of-care molecular testing platform.  

Veros is described as the first and only self-contained, single-use COVID-19 product that produces PCR-quality results in approximately 15 minutes, unconstrained by a reader or need for external power.

“This agreement is significant for Sense as it marks our entry into the South American market,” said Sense chief commercial officer Ryan Roberts. 

“Together with Biotecom, we believe that by adding the instrument-free Veros COVID-19 to their portfolio, healthcare providers in Chile will be able to provide faster diagnosis and exceptional care for their patients right at the point of use by taking advantage of this rapid, laboratory-quality molecular test.”

Founded in 2013, Biotecom is a leading specialty medical distributor of biotechnology and molecular devices serving Chilean hospitals, laboratories, and clinics.

Sense has also tied up a deal with Bio Nuclear Diagnostics, Inc. for the non-exclusive distribution in Canada of Veros, strengthening its muscle in North America.

Bio Nuclear Diagnostics is a leading specialty medical distributor with proven success in creating value by connecting innovative manufacturers with customers in Canada. 

As the virus continues to evolve, Veros COVID-19 has maintained the ability to detect all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants.